{"id":30698,"date":"2025-08-25T05:54:12","date_gmt":"2025-08-25T05:54:12","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/harbour-biomed-appoints-yajie-li-as-chief-medical-officer\/"},"modified":"2025-08-25T05:54:12","modified_gmt":"2025-08-25T05:54:12","slug":"harbour-biomed-appoints-yajie-li-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=30698","title":{"rendered":"Harbour BioMed Appoints Yajie Li as Chief Medical Officer"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SHANGHAI<\/span><\/span>, Aug. 25, 2025<\/span><\/span> \/PRNewswire\/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li<\/span> as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai<\/span> and report directly to Dr. Jingsong Wang<\/span>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.<\/p>\n

\n<\/div>\n

In this role, Ms. Li will lead clinical development, regulatory strategy, and medical affairs for the company’s clinical-stage programs. She will also play a key role in evaluating early-stage assets based on unmet medical needs, clinical value, and scientific differentiation.<\/p>\n

Ms. Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs including Merck, Johnson & Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China<\/span> (NMPA)\/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas.<\/p>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman, and CEO of Harbour BioMed,\u00a0commented: “We are very pleased to welcome Yajie Li<\/span> to our executive team. Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world.”<\/p>\n

Yajie Li<\/span>, Chief Medical Officer of Harbour BioMed, added: “It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth. The company’s cutting-edge antibody technology platform and global R&D strategy is well positioned to deliver innovative therapies in areas of high unmet need. I look forward to working with the team to accelerate clinical development, enhance regulatory alignment, and bring meaningful treatments to patients worldwide.”<\/p>\n

Ms. Li holds a master’s degree in Rheumatology and Immunology from Peking Union Medical College.<\/p>\n

About Harbour BioMed<\/b><\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.<\/p>\n

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice\u00ae<\/sup>, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae<\/sup>) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM<\/sup>) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice\u00ae<\/sup>, HBICE\u00ae<\/sup>, and HBICATM<\/sup> with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SHANGHAI<\/span><\/span>, Aug. 25, 2025<\/span><\/span> \/PRNewswire\/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li<\/span> as Chief Medical Officer (CMO). Ms. Li will be based in Shanghai<\/span> and report directly to Dr. Jingsong Wang<\/span>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.<\/p>\n

\n<\/div>\n

In this role, Ms. Li will lead clinical development, regulatory strategy, and medical affairs for the company’s clinical-stage programs. She will also play a key role in evaluating early-stage assets based on unmet medical needs, clinical value, and scientific differentiation.<\/p>\n

Ms. Li brings over a decade of experience in the pharmaceutical industry, with leadership roles in clinical development and regulatory affairs at multinational corporations and CROs including Merck, Johnson & Johnson and Parexel, as well as at Chinese biopharma companies such as GenSci, XuanZhu Biopharm, and Innovent. Prior to her industry career, she served for nine years as a Senior Medical Officer at the National Medical Products Administration of China<\/span> (NMPA)\/Center for Drug Evaluation (CDE), where she contributed to regulatory assessments across a broad range of therapeutic areas.<\/p>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman, and CEO of Harbour BioMed,\u00a0commented: “We are very pleased to welcome Yajie Li<\/span> to our executive team. Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world.”<\/p>\n

Yajie Li<\/span>, Chief Medical Officer of Harbour BioMed, added: “It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth. The company’s cutting-edge antibody technology platform and global R&D strategy is well positioned to deliver innovative therapies in areas of high unmet need. I look forward to working with the team to accelerate clinical development, enhance regulatory alignment, and bring meaningful treatments to patients worldwide.”<\/p>\n

Ms. Li holds a master’s degree in Rheumatology and Immunology from Peking Union Medical College.<\/p>\n

About Harbour BioMed<\/b><\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.<\/p>\n

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice\u00ae<\/sup>, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae<\/sup>) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM<\/sup>) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice\u00ae<\/sup>, HBICE\u00ae<\/sup>, and HBICATM<\/sup> with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-30698","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30698"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30698\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}